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Abstract
Background—Antiretroviral interventions are used to reduce HIV viral replication and prevent 
mother-to-child transmission. Viral suppression relies on adherence to antiretrovirals.
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Methods—A two-phase study was conducted using data from the Breastfeeding, Antiretrovirals 
and Nutrition study. We included mothers randomized to 28 weeks of postpartum antiretrovirals 
with ≥1 plasma or breastmilk specimen. All mothers who transmitted HIV to their infants from 
2-28 weeks (n=31) and 15% of mothers who did not (n=232) were included. Adherence was 
measured by pill count [categorized as poor (0-80%), partial (81-98%) and near perfect (>98%)]. 
Associations between adherence and breastmilk RNA were assessed using mixed effects models. 
Cox models were used to estimate associations between breastmilk RNA and HIV transmission. 
Using Monte Carlo simulation, we estimated the number of transmissions that would occur had 
everyone randomized to maternal ARVs been 90% and 100% adherent.
Results—Partial or near perfect antiretroviral adherence significantly reduced the odds of having 
detectable (≥40 copies/ml) breastmilk RNA, compared to poor adherence (OR 0.23, 95% CI 
0.08-0.67; OR 0.36, 95% CI 0.16-0.81, respectively). Detectable breastmilk RNA was associated 
with increased breastmilk transmission, compared to undetectable breastmilk RNA (HR 3.8, 95% 
CI 1.2-12.1). All transmitting mothers had ≥1 plasma viral load specimen >100 copies/ml. An 
estimated similar number of transmissions would occur with 90% adherence compared with 
100%.
Conclusions—Helping patients adhere to antiretrovirals throughout breastfeeding is important 
for realizing the full potential of recommended antiretroviral interventions to prevent mother-to-
child HIV transmission. Maintaining plasma viral load <100 copies/ml may prevent breastmilk 
transmission.
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Introduction
Maternal HIV RNA concentration (viral load or VL) in plasma and breastmilk is among the 
most important risk factors for HIV transmission during breastfeeding.1-3 Transmission 
through breastmilk is thought to be due to two potential mechanisms. First, cell-associated 
virus or cell-free virions may continually traffic from blood into breastmilk.4 Second, virus 
may be transiently produced locally.4, 5 Both cell-associated and cell-free virus in breastmilk 
appear to increase HIV transmission. To date, no breastmilk viral threshold has been 
identified below which breastmilk HIV transmission has not occurred.6, 7
Breastmilk transmission is thought to occur when infant ingestion of cell-free or cell-
associated virus is absorbed in mucosal gut surfaces, tonsils, or adenoids.8 To prevent 
mother-to-child HIV transmission (PMTCT), antiretroviral (ARV) interventions have been 
used to reduce HIV viral replication in breastmilk and maternal blood. Adherence to ARV 
regimens is necessary to achieve and maintain therapeutic plasma drug levels, and in turn 
plasma viral suppression.9, 10 However, ARV concentrations in breastmilk differ within and 
between classes of drugs.11 Nevirapine passes into breastmilk, with breastmilk 
concentrations 67-90% those of mother's plasma. Zidovudine and lamivudine have higher 
exposures in breastmilk than maternal plasma.5, 12
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In this study, we use a comprehensive approach to assess the role of adherence on HIV 
transmission by assessing the causal pathway that includes both maternal plasma and 
breastmilk HIV VL. We then compare the estimated number of transmissions that would 
have occurred from 2-28 weeks postpartum if all mothers randomized to maternal ARVs had 
been 0%, 90%, and 100% adherent.
Methods
The Breastfeeding, Antiretrovirals and Nutrition (BAN) study, conducted in Lilongwe, 
Malawi to assess the benefit and safety of maternal or infant ARVs to prevent HIV 
transmission during breastfeeding, recruited and followed HIV-infected pregnant women 
from antenatal clinics in 2004-2010. Eligibility criteria for mother-infant pairs included: 
maternal CD4+ ≥250 cells/μL (≥200 cells/μL before July 24, 2006), no previous ARV drug 
use (including single dose nevirapine [NVP]), infant birth weight ≥2000 grams, no condition 
that would preclude use of study drug, and enrollment <36 hours after delivery.13
Details of the BAN Study have been reported previously.14, 15 Briefly, mothers were 
randomized after birth via factorial design to receive or not receive a lipid-based nutrient 
supplement throughout breastfeeding and to receive one of the following postpartum 
PMTCT regimens: 1) 28 weeks of maternal triple ARVs (maternal ARV); 2) 28 weeks of 
infant NVP; or 3) no further drugs postpartum.13 All mothers and infants received one dose 
of NVP at delivery or birth and seven days of postpartum zidovudine and lamivudine.13 
Mothers were counseled to exclusively breastfeed for 24 weeks and wean from 24-28 weeks 
postpartum.13 Ethical approval was obtained from the Malawi National Health Science 
Research Committee and the institutional review boards at the University of North Carolina 
at Chapel Hill and the U.S. Centers for Disease Control and Prevention.
Study design
Using a cohort study design with two-phase sampling 16, we included all mothers in the 
maternal ARV or infant NVP arms with ≥1 available plasma or breastmilk sample between 
2-24 weeks postpartum and an HIV transmission event between 2-28 weeks postpartum 
(n=31, 94% of transmission events). We also included 15% of mothers randomized to the 
two treatment arms of BAN who did not transmit HIV to their infant by 28 weeks 
postpartum (n=232); sampling was primarily based on stored specimen availability. When 
multiple births occurred only first-born multiples were included (n=5). Our analysis 
included a total of 263 mothers at risk of transmitting HIV via breastmilk from 2-28 weeks 
postpartum.
Adherence measures
Maternal adherence was calculated using pill counts taken by trained pharmacy staff on 
contiguous visits for the following postpartum time intervals: 2-4, 8-12, and 13-18 weeks. 
Specifically, adherence was calculated by dividing the difference in the number of pills 
distributed and returned by the number of pills expected to be consumed under perfect 
compliance.17 The observed distribution of maternal pill count adherence was skewed, with 
most women randomized to maternal ARVs having adherence values greater than 90%. The 
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observed adherence distribution was anticipated due to mothers' high motivation to adhere to 
study drug in order to prevent HIV transmission to their infant. Mothers randomized to the 
infant NVP arm were assigned a maternal adherence value of zero for all intervals. In our 
main analyses, maternal adherence was categorized as poor (0-80%), partial (81-98%) and 
near perfect (>98%) using disjoint indicator variables. Categories were chosen based on 
previous studies and the observed adherence distribution, allowing for a relatively balanced 
number of observations across three adherence categories (poor, partial, and near perfect 
adherence). In sensitivity analyses, we treated adherence as a dichotomous variable (>90% 
versus ≤90%, and >80% versus ≤80%).
HIV RNA and DNA testing
HIV RNA was quantified from blood plasma and whole breastmilk at enrollment, 2, 6, 12, 
18, and 24 weeks postpartum. In addition, breastmilk HIV RNA was measured at 4 and 8 
weeks postpartum. Plasma VL was quantified using the Abbott RealTime HIV assay (Abbott 
Molecular, Des Plaines, IL) by the 0.6ml protocol according to the package insert (lower 
limit of quantitation 40 copies/ml). Breastmilk VL was quantified from 0.6 ml whole 
breastmilk pre-treated with 209μl Abbott RNA sample prep lysis buffer and 60μl Abbott 
Proteinase K (53°C incubation for 20 min) using the Abbott RealTime HIV assay (lower 
limit of quantitation 56 copies/ml). HIV RNA concentrations that were detected but below 
the limit of quantitation were assigned a value of 39 for plasma and 55 for breastmilk, and 
RNA concentrations that were undetectable were assigned a value equal to 50% of the lower 
limit of quantitation (plasma: 20, breastmilk: 28).
Infant HIV status was determined at 2, 12, 28, and 48 weeks by Roche Amplicor 1.5 DNA 
PCR (Roche Molecular Systems, Pleasanton, CA, USA). PCR positive results were 
confirmed by testing an additional blood specimen. The window of infection was narrowed 
by testing infant dried blood-spots collected at 4, 6, 8, 18, 24, and 32 weeks. Breastmilk 
transmission was defined as first detection of HIV infection by PCR in infant blood between 
2-28 weeks of age. Infants who tested HIV-1 DNA PCR positive at either birth or by two 
weeks of age were considered to be infected in utero or intrapartum and were excluded from 
all BAN analyses of breastmilk transmission. Sensitivity of HIV-1 DNA PCR for diagnosing 
intrapartum HIV transmission has been shown to reach 93% by 14 days of age, thus most 
perinatal infections will be detected within two weeks of birth.18
Data Analyses
We used generalized linear mixed models with a random effect (i.e., random intercept) for 
each mother-infant pair. Identity link and Gaussian distribution were used to estimate 
differences in log10 plasma VL by adherence category, and logit link with binomial 
distribution were used to estimate odds ratios for detectable breastmilk VL by adherence and 
plasma VL category. Adherence was paired with VL measured at the end of the adherence 
time interval. Therefore, only VL information from 6, 12, and 18 weeks postpartum was 
used when adherence was the exposure. The reciprocal of the study inclusion probability 
was used as a sampling weight in all regression analyses to account for the two-phase 
sampling.19
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Single and multivariable Cox models were used to estimate the relative hazard of breastmilk 
HIV transmission by 28 weeks. Breastmilk VL was treated as a time-varying covariate in 
Cox models, lagged by one interval. Time until infant HIV infection was right censored at 
the first occurrence of the following: time of infant death, time of infant's last PCR negative 
test if lost to follow-up or at 28 weeks if the infant remained HIV-uninfected, or at reported 
cessation of breastfeeding unless HIV transmission occurred within 30 days of reported 
cessation.14
Effect measure modification was assessed by comparing unadjusted and adjusted estimates 
and 95% confidence intervals using an interaction term between the exposure and variable of 
interest. Study arm was identified as an effect measure modifier when assessing the 
association between breastmilk viral load and HIV transmission. No other effect measure 
modification was identified. A directed acyclic graph was used to identify potential 
confounders and a minimally sufficient adjustment set.20 Potential confounding variables 
consisted of randomization assignment, demographic characteristics, and health status 
information collected at enrollment (hereafter referred to as baseline) (Table 1). Missing 
adherence and VL measures were accounted for using multiple imputation21 assuming data 
were missing at random.
Monte Carlo simulation was used to estimate the number of transmissions that would have 
occurred if all mothers randomized to maternal ARVs (n=848) had been 0%, 90%, and 
100% adherent. Data sets with the same sample size as the maternal ARV arm of BAN were 
simulated under four adherence scenarios. Under the first scenario, longitudinal adherence 
values were generated by randomly sampling from the observed adherence values for all 
mothers in the maternal ARV arm. Under the remaining scenarios, all mothers were 
simulated to be 0%, 90%, and 100% adherent. Simulation results from the first scenario 
were compared with the actual observed data from BAN to ensure the simulation model was 
correctly calibrated. For all scenarios, time-varying breastmilk VLs were then randomly 
generated using the fitted mixed effects logistic regression model from the observed data 
conditional on simulated adherence values. A transmission time of infant HIV infection was 
then simulated based on a Cox model with constant baseline hazard and simulated time-
varying breastmilk VL. Censoring times were simulated in accordance with the 12% 
observed dropout in BAN. Finally, the number of infant infections estimated to have 
occurred with 0%, 90%, and 100% adherence were compared.
All data analyses were conducted using SAS version 9.3 (SAS Institute, Cary, North 
Carolina, USA) and R version 3.0.2 (R Core Team, Vienna, Austria).
Results
Baseline characteristics of mother-infant pairs included in this two-phase study were 
comparable to those in the full BAN cohort (Table 1).13 At baseline, mothers had a median 
CD4+ count of 408/μL (IQR: 301-544), log10 plasma VL of 4.4 (IQR: 3.8-4.9), and 
hemoglobin of 10.6 g/dl (IQR: 9.7-11.5).
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Overall median log10 plasma VL did not meaningfully differ between transmitting and non-
transmitting mothers randomized to infant NVP (4.1 and 4.2 copies/ml, respectively), nor 
between transmitting mothers randomized to infant NVP and transmitting mothers 
randomized to maternal ARVs (4.1 and 3.9 copies/ml, respectively) (Table 2). However, 
overall median log10 plasma VL was two logs less among non-transmitting mothers 
randomized to maternal ARVs (2.2 copies.ml) compared to the aforementioned.
A greater percentage of transmitting mothers had detectable breastmilk VL compared with 
non-transmitters at nearly all time points, regardless of study arm (Table 2). However, 85% 
(540/632) of breastmilk specimens from the maternal ARV arm had undetectable virus, 
compared to 56% (385/691) for women enrolled in the infant NVP arm. Median log10 
breastmilk VL was similar between breastmilk specimens from transmitting and non-
transmitting mothers and between breastmilk specimens from mothers randomized to the 
maternal ARV and infant NVP arms, due in part to the large number of specimens with 
undetectable virus.
Adherence and HIV viral load
At least one paired maternal adherence and plasma HIV VL was available for 245 (93%) 
mothers meeting our study inclusion criteria. Among mothers in the maternal ARV arm, 
overall mean adherence was 88% [median 0.96, IQR 0.86-1.00] at 2-18 weeks postpartum 
and most received a boosted protease inhibitor regimen of zidovudine, lamivudine, and 
lopinavir/ritonavir (70%). Based on the unadjusted model, having partial adherence was 
associated with a 0.82 (95% confidence interval (CI) 0.55-1.09) log10 reduction in plasma 
VL compared to having poor adherence (Table 3). Having near perfect adherence was 
associated with a 0.69 (95% CI 0.45-0.93) log10 reduction in plasma VL compared to poor 
adherence. Adjusting for nutritional randomization and baseline maternal characteristics 
yielded similar results. Multiple imputation produced similar though attenuated associations 
between increased adherence and lower plasma VL.
Maternal adherence had an analogous association with suppression of virus in breastmilk. 
Among 211 (80%) mothers with paired adherence and breastmilk HIV VL data, partial 
adherence and near perfect adherence were associated with a 76% (95% CI 28-92%) and a 
62% (95% CI 14-83%) relative reduction in the odds of having detectable breastmilk VL, 
respectively, compared to poor adherence (Table 4). Adjustment for potential confounding 
variables did not appreciably change the estimates or precision. The associations remained 
similar but less precise when using multiple imputation. Results are not presented for the 
strata of mothers randomized to infant NVP, as they did not contribute to the >80-98% or 
>98% adherence categories.
In sensitivity analyses, adherence was treated as a dichotomous variable (>90% versus 
≤90%, and >80% versus ≤80%). Choice of adherence categorization did not change our 
overall conclusions, as higher adherence remained associated with reduced log10 plasma 
viral load and reduced odds of detectable breastmilk viral load, compared with lower 
adherence (data not shown).
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Plasma and breastmilk HIV viral load
Among the 221 (84%) mothers with ≥1 paired plasma and breastmilk HIV VL, mothers with 
detectable breastmilk VL typically had detectable plasma VL. Two (<1%) mothers had 
detectable breastmilk VL (56 and 77 copies/ml) and undetectable plasma VL at 6 weeks 
postpartum. Mothers with a detectable plasma VL had 59 (95% CI 21-169) times the odds of 
having a detectable breastmilk VL, compared with mothers with an undetectable plasma VL 
(Table 4). Adjusting for study arm, baseline maternal CD4+ count, and baseline maternal 
plasma VL resulted in a slightly attenuated association between detectable plasma and 
breastmilk VL (OR 40, 95% CI 15-107). Using multiple imputation produced similar though 
attenuated findings.
Plasma viral load and HIV transmission
At least one plasma VL between 2-24 weeks postpartum was available for 27 of 33 (82%) 
mothers of HIV-infected infants. Among these, one transmission event occurred from a 
mother with undetectable baseline plasma VL. However, transmission occurred at 24 weeks 
postpartum and after three VL measures ranging from 8,000-108,000 copies/ml. The 
remaining 26 transmitting mothers had baseline plasma VL>3500 copies/ml.
Among 116 mothers with complete plasma VL information, five had undetectable plasma 
VL at all measured time points between 2-24 weeks. All five were in the maternal ARV arm, 
also had undetectable breastmilk VL at all measured time points, and none transmitted HIV 
to their infant. Additionally, plasma VL from the time point immediately preceding 
transmission was available for 21 mothers, with VL ranging from 102 to >636,000 
copies/ml. No mother who consistently maintained a plasma viral load <100 copies/ml 
transmitted HIV to her infant during breastfeeding.
Breastmilk viral load and HIV transmission
Complete time-dependent breastmilk VL and infant HIV status were available for 134 (51%) 
mothers. Of these, 15 experienced a HIV transmission event between 2-28 weeks 
postpartum (maternal ARV arm: 11, infant NVP arm: 4). Among these 15 mothers, 11 
(73%) had at least one detectable breastmilk VL before transmission occurred, and 8 (53%) 
had a detectable breastmilk VL at the last measured time point before transmission.
Using multiply imputed data (n=31 transmission events), detectable breastmilk VL was 
associated with 3.8 (95% CI 1.2-12.1) times the rate of breastmilk HIV transmission, 
compared with undetectable breastmilk VL after adjusting for study arm and baseline 
maternal characteristics (Table 5). Breastmilk VL had a somewhat diminished association 
with HIV transmission in unadjusted analyses (HR 2.9, 95% CI 1.0-8.4). In complete case 
analyses, detectable breastmilk VL had a similar unadjusted and increased adjusted 
association with HIV transmission (unadjusted HR 2.7, 95% CI 1.4-5.4; adjusted HR 7.4, 
95% CI 3.2-17.1). However, the adjusted complete case analysis results should be 
interpreted with caution due to the number of adjustment factors and limited number of 
transmission events.
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Using Monte Carlo simulation, the calibration model predicted the same number of HIV 
transmissions between 2-28 weeks postpartum as observed in the maternal ARV arm of 
BAN (n=21). If all 848 mothers randomized to maternal ARVs had been 100% adherent, the 
model predicted 20.4 transmissions (95% prediction interval (PI) 12, 30). In contrast, if all 
of these mothers had been 0% adherent, the model predicted 42.3 transmissions (95% PI 30, 
56), indicating an average of approximately 22 infections averted due to perfect maternal 
ARV adherence. Simulations where all 848 women were 90% adherent yielded similar 
results (20.5 transmission, 95% PI 12, 30) to the 100% adherence scenario.
Discussion
We have shown that better adherence is associated with lower breastmilk HIV RNA and 
lower risk of transmission of HIV to the infant. We also estimated that a similar number of 
infant infections would have occurred with 90% maternal ARV adherence as estimated to 
have occurred with 100% maternal ARV adherence. While we were able to detect HIV RNA 
at lower concentrations than several previous studies, we were unable to identify a 
breastmilk HIV RNA threshold below which transmission did not occur. However, no 
transmissions occurred when maternal plasma VL was consistently <100 copies/ml.
Non-adherence to ARVs has been associated with higher plasma HIV VL in pregnant 
women.22 Similarly, we found non-adherence to postpartum maternal ARVs to be associated 
with substantially higher plasma and breastmilk HIV RNA concentration during the 
breastfeeding period, and we provide the first estimates of the association between maternal 
ARV adherence and breastmilk HIV VL. In addition, plasma VL has been correlated with 
breastmilk VL.1, 22, 23 Using more frequently measured paired plasma and breastmilk 
specimens, we also found a strong positive association between plasma and breastmilk HIV 
RNA concentration for mothers randomized to maternal ARVs and mothers randomized to 
infant NVP.
The adherence levels and breastmilk HIV RNA concentration found in BAN are similar to 
levels found in previous studies,7, 23-27 although direct comparisons are difficult due to 
differences in adherence measurement and viral assays, and the variety of thresholds used to 
define adherence and detectable VL. Nonetheless, we previously found consistent 
associations between adherence and breastmilk HIV transmission in BAN using pill count 
and self-reported adherence.17
Detectable breastmilk HIV VL and breastmilk HIV transmission occurred despite apparently 
perfect (100%) maternal ARV pill count adherence. This observation may be due to 
imperfection in our adherence measure, length of time between maternal initiation of 
antiretrovirals and viral suppression, mastitis, antiretroviral drug resistance, low levels of 
antiretrovirals in breastmilk, or other unidentified processes. In addition, adherence was held 
constant during the interval, and therefore may not reflect true adherence at the time 
immediately preceding the VL measure. Breastmilk HIV transmission also occurred despite 
undetectable breastmilk HIV VL, possibly due to periods of detectable breastmilk VL at 
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unmeasured time points, or persistent cell-associated HIV viral reservoirs in breastmilk not 
eliminated with triple ARVs. 28-31
Detectable breastmilk HIV VL was associated with HIV transmission among mothers 
randomized to maternal antiretrovirals. Among mothers randomized to infant NVP, 
detectable breastmilk HIV VL also appeared to be associated with breastmilk HIV 
transmission, though the small number of transmission events limited our ability to make 
conclusions by study arm.
Slightly stronger associations between adherence and both plasma and breastmilk VL were 
estimated in the partial adherence group, compared to the near perfect adherence group. This 
paradoxical result may be due to adherence measurement error, including the possibility that 
partial adherers report more accurate pill returns whereas perfect adherers may return only 
the number of pills expected. However, both adherence categories were associated with 
reduced plasma and breastmilk HIV RNA concentration.
The limited number of available paired adherence and VL measures among mothers in the 
maternal ARV arm affected the precision of our estimates, and limited our ability to make 
conclusions by ARV study arm. Missing breastmilk viral load data were predominantly due 
to BAN Study protocol amendments which reduced the frequency of breastmilk collection in 
order to decrease staff workload and save costs. Complete description of BAN Study 
protocol amendments and their rationale have been previously published.32 Missing 
adherence and VL measures were multiply imputed. Similar, though often attenuated, 
associations were seen for all contrasts when multiply imputed data were used. No 
substantial gains in precision were seen when using multiply imputed data, potentially due 
to the number of outcomes that had to be imputed and the lack of strong auxiliary 
variables.33 However, mixed effects models are consistent under the missing at random 
assumption, increasing the confidence in our analogous findings using both complete case 
and multiply imputed data.
As we have previously shown, antiretroviral adherence needs to be maintained to maximize 
PMTCT efforts and increase infant HIV-free survival.17 However, we now more 
conclusively show that maintaining antiretroviral adherence alone is unlikely to prevent all 
breastmilk transmission in the first 28 weeks postpartum if triple ARVs are initiated after 
delivery. The sufficient set of mechanisms that cause breastmilk HIV transmission remain 
incompletely determined. Provision of lifelong maternal ARV therapy to all pregnant and 
breastfeeding women, with currently available ARVs, will likely have to be implemented in 
concert with other prevention interventions to eliminate breastmilk HIV transmission.34
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Table 1




 Maternal antiretroviral 129 (49)
 Infant nevirapine 134 (51)
Nutritional randomization
 No supplement 125 (48)
 Received supplement 138 (52)
Mothers:
Age (years)
 15-25 144 (55)
 26-35 105 (40)
 36-45 13 (5)
Education (primary school only) 173 (66)
Married 242 (92)
Parity ≥1 227 (86)
CD4+ count per mm3
 200-350 95 (36)
 351-500 81 (31)
 >500 87 (33)
Plasma viral load copies/ml
  ≤ 1,000 20 (8)
  1,001-10,000 60 (23)
  > 10,000 181 (69)
Hemoglobin <11 g/dl 160 (61)
Antiretroviral regimen**
 Nevirapine based 5 (4)
 Nelfinavir based 29 (26)
 Lopinavir/ritonavir based 78 (70)
Infants:
Sex (female) 139 (53)
Birth weight <2.5 kg 27 (10)
*
Maternal age is missing for 1 mother, baseline plasma viral load is missing for 2 mothers, and antiretroviral (ARV) regimen is missing for 17 
mothers assigned to maternal ARVs
**
Among mothers randomized to maternal ARV arm
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